FDA ap­proves Ital­far­ma­co’s drug Du­vyzat for Duchenne mus­cu­lar dy­s­tro­phy

The FDA ap­proved the first non­s­teroidal drug to treat all ge­net­ic vari­ants of Duchenne mus­cu­lar dy­s­tro­phy, clear­ing drug­mak­er Ital­far­ma­co’s oral treat­ment for pa­tients age 6 and old­er.

The drug, givi­no­s­tat, will be sold as Du­vyzat, the FDA said in a press re­lease an­nounc­ing the ap­proval. It’s dif­fer­ent than ge­net­ic med­i­cines ap­proved for Duchenne, such as ex­on-skip­ping drugs or gene ther­a­py, which re­quire pa­tients to have cer­tain mu­ta­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER